This study demonstrates that FGFR1 inhibition with pemigatinib offers a promising strategy for overcoming the intrinsic radioresistance of GBM, including its most treatment-refractory subpopulations such as GSCs and MGMT-unmethylated tumors. The gene discussed is MGMT; the disease is glioblastoma.